Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

Breast Cancer Clinical Trial

Official title:

Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclitaxel for ER-, PR-, Her2- (Triple Negative) Early-Stage Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01194869
• Other study ID #: IRB00019781
• Secondary ID: WCI1590-08
• Status: Terminated
• Phase: Phase 2
• First received: September 1, 2010
• Last updated: August 5, 2015
• Start date: June 2010
• Est. completion date: June 2015

Study information

• Verified date: August 2015
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of cisplatin and sorafenib followed by paclitaxel and sorafenib can shrink the size of your breast tumor and allow you to preserve your breast. Sorafenib is a newer drug that targets blood vessel formation and may help the chemotherapy work better. Additionally, by receiving chemotherapy before surgery, we will be able to determine if your cancer is responsive to chemotherapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed invasive breast carcinoma.

• Early stage breast cancer (Stage I (tumor size = 1cm), II and IIIA).

• Invasive breast cancer must be ER-negative, PR-negative, Her2-negative. If breast cancer is Her2 2+ by immunohistochemistry (IHC), then FISH must be negative for Her2 gene amplification.

• No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes.

• Patients must have measurable disease as defined by palpable lesion with both diameters = 1cm measurable with caliper and/or a positive mammogram or ultrasound with at least one dimension = 1cm. Screening mammogram of the contralateral breast must be performed within past 12 months per standard practice guidelines. Clip placement is required for study entry. Baseline measurements of the indicator lesions must be recorded on the Patient Registration Form. To be valid for baseline, the measurements on clinical exam must have been made within 14 days if the mass is palpable. If the mass is not palpable, a mammogram or MRI must be done within 14 days. If the mass is palpable, a diagnostic mammogram of the affected breast or MRI must be done within 2 months prior to study entry.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 14 days of study entry.

• Normal (greater than 50%) left ventricular ejection fraction (LVEF) by multigated acquisition (MUGA) scan or echocardiography.

• Signed informed consent.

• Adequate organ function within 2 weeks of study entry:

• Absolute neutrophil count = 1000/mm³, Hgb = 9.0 g/dl and platelet count = 100,000/mm³

• Total bilirubin = upper limit of normal

• Creatinine = 1.5 mg/dL or calculated creatinine clearance (CrCL) = 50 mL/min using the Cockroft Gault equation

• Serum glutamic oxaloacetic transaminase (SGOT)(AST) or serum glutamic pyruvic transaminase (SGPT)(ALT) and alkaline phosphatase must be within the range allowing for eligibility

• Patients must be = 18 years.

• International normalized ratio (INR) < 1.5 or a prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable.

• Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.

• Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation.

• Patients with history of breast cancer greater than 5 years from initial diagnosis and are disease free are eligible for the study. Patients with history of ductal carcinoma in situ (DCIS) are eligible if there were treated with surgery alone.

Exclusion Criteria:

• Prior chemotherapy, hormonal therapy, biologic therapy, investigational agent, targeted therapy or radiation therapy for current breast cancer.

• Metastatic disease on baseline staging scans.

• Medical, psychological or surgical condition which the investigator feels might compromise study participation.

• History of previous or current malignancy at other sites with the exception of adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma of the skin. Patients with a history of other malignancies, who remain disease free for greater than five years are eligible.

• Evidence of grade 2 or greater sensory and/or peripheral neuropathy.

• Serious, uncontrolled, concurrent infection(s).

• Major surgery within 4 weeks of the start of study treatment, without complete recovery.

• Pregnant or lactating women are not eligible. Women or men of childbearing potential not using a reliable and appropriate contraceptive method are not eligible. (Postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential).

• Use of St. John's Wort or rifampin (rifampicin).

• Known or suspected allergy to sorafenib or any agent given in the course of this trial.

• Any condition that impairs patient's ability to swallow whole pills.

• Any malabsorption problem.

• Evidence or history of bleeding diathesis or coagulopathy.

• Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.

• Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.

• Pulmonary hemorrhage/bleeding event = Common Toxicity Criteria for Adverse Effects (CTCAE) Grade 2 within 4 weeks of first dose of study drug.

• Any other hemorrhage/bleeding event = CTCAE Grade 3 within 4 weeks of first dose of study drug.

• Cardiac disease: congestive heart failure > class II New York Heart Association (NYHA). Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.

• Known brain metastasis. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis.

• Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

• Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Sorafenib
Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.

Locations

Country	Name	City	State
United States	Emory University Hospital Midtown	Atlanta	Georgia
United States	Emory University Winship Cancer Institute	Atlanta	Georgia
United States	Grady Memorial Hospital	Atlanta	Georgia

Sponsors (3)

Lead Sponsor	Collaborator
Emory University	Bayer, Onyx Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of pathologic complete response rate at the time of surgery after preoperative treatment		at the time of surgery, after 24 weeks of preoperative treatment	No
Secondary	Clinical response rate, safety, disease-free survival, overall survival		during 24 weeks of therapy and during routine follow-up after study completion	Yes